fabrizio De Benedetti

List of Publications by Year
in descending order

297	15,122	19636 61	20943 115
papers	citations	h-index	g-index

307	307	307	15222
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2385-2395.	13.9	716
2	On the Alert for Cytokine Storm: Immunopathology in <scp>COVID</scp>â€19. Arthritis and Rheumatology, 2020, 72, 1059-1063.	2.9	562
3	Interleukin 6 Is Required for the Development of Collagen-induced Arthritis. Journal of Experimental Medicine, 1998, 187, 461-468.	4.2	545
4	Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.. Journal of Clinical Investigation, 1997, 99, 643-650.	3.9	449
5	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2016, 68, 566-576.	2.9	427
6	American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care and Research, 2011, 63, 929-936.	1.5	391
7	Translating IL-6 biology into effective treatments. Nature Reviews Rheumatology, 2020, 16, 335-345.	3.5	369
8	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.5	338
9	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	13.9	327
10	Correlation of Serum Interleukin-6 Levels with Joint Involvement and Thrombocytosis in Systemic Juvenile Rheumatoid Arthritis. Arthritis and Rheumatism, 1991, 34, 1158-1163.	6.7	325
11	Macrophage activation syndrome in the era of biologic therapy. Nature Reviews Rheumatology, 2016, 12, 259-268.	3.5	323
12	Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. New England Journal of Medicine, 2020, 382, 1811-1822.	13.9	320
13	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.5	300
14	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Annals of the Rheumatic Diseases, 2011, 70, i2-i36.	0.5	287
15	Impaired skeletal development in interleukin-6â€“transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis and Rheumatism, 2006, 54, 3551-3563.	6.7	271
16	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases, 2015, 74, 1110-1117.	0.5	251
17	Mutation screening of the macrophage migration inhibitory factor gene: Positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2002, 46, 2402-2409.	6.7	242
18	Inhibition of Natural Killer Cell Cytotoxicity by Interleukinâ€6: Implications for the Pathogenesis of Macrophage Activation Syndrome. Arthritis and Rheumatology, 2015, 67, 3037-3046.	2.9	222

#	ARTICLE	IF	CITATIONS
19	Elevated circulating levels of interferon-Î³ and interferon-Î³-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2017, 76, 166-172.	0.5	222
20	Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.. Journal of Clinical Investigation, 1994, 93, 2114-2119.	3.9	216
21	Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology, 2010, 49, 441-449.	0.9	202
22	NGF and Its Receptors in the Regulation of Inflammatory Response. International Journal of Molecular Sciences, 2017, 18, 1028.	1.8	192
23	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213030.	0.5	183
24	Functional and prognostic relevance of the ?173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2003, 48, 1398-1407.	6.7	173
25	Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood, 1996, 87, 4824-4830.	0.6	169
26	An International registry on Autoinflammatory diseases: the Eurofever experience. Annals of the Rheumatic Diseases, 2012, 71, 1177-1182.	0.5	158
27	Effect of IL-6 on IGF Binding Protein-3: A Study in IL-6 Transgenic Mice and in Patients with Systemic Juvenile Idiopathic Arthritis. Endocrinology, 2001, 142, 4818-4826.	1.4	147
28	Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14384-14389.	3.3	139
29	Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. Journal of Pediatrics, 1996, 128, 275-278.	0.9	134
30	Cisternal CSF levels of cytokines after subarachnoid hemorrhage. Neurological Research, 1998, 20, 337-342.	0.6	133
31	A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. Journal of Experimental Medicine, 2019, 216, 2778-2799.	4.2	132
32	A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2004, 50, 1604-1610.	6.7	124
33	Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. Pediatric Rheumatology, 2017, 15, 5.	0.9	123
34	Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome. Journal of Pediatrics, 2004, 145, 851-855.	0.9	122
35	Emergent high fatality lung disease in systemic juvenile arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1722-1731.	0.5	122
36	Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humans. Journal of Bone and Mineral Research, 2011, 26, 1891-1903.	3.1	116

#	ARTICLE	IF	CITATIONS
37	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: TableÂ1. Annals of the Rheumatic Diseases, 2013, 72, ii2-ii34.	0.5	114
38	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Annals of the Rheumatic Diseases, 2010, 69, i2-i29.	0.5	113
39	Interleukin-1Î² and Interleukin-6 in Arthritis Animal Models: Roles in the Early Phase of Transition from Acute to Chronic Inflammation and Relevance for Human Rheumatoid Arthritis. Molecular Medicine, 2010, 16, 552-557.	1.9	100
40	Amplification of the response to Tollâ€like receptor ligands by prolonged exposure to interleukinâ€6 in mice: Implication for the pathogenesis of macrophage activation syndrome. Arthritis and Rheumatism, 2012, 64, 1680-1688.	6.7	100
41	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Annals of the Rheumatic Diseases, 2008, 67, iii2-iii25.	0.5	99
42	Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2018, 70, 409-419.	1.5	96
43	Neutralization of IFN-Î³ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. Journal of Allergy and Clinical Immunology, 2018, 141, 1439-1449.	1.5	96
44	c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling. Nature Communications, 2012, 3, 630.	5.8	93
45	Nerve Growth Factor Downregulates Inflammatory Response in Human Monocytes through TrkA. Journal of Immunology, 2014, 192, 3345-3354.	0.4	91
46	An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, 71, 2272-2275.	2.9	91
47	Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. Journal of Clinical Immunology, 2019, 39, 476-485.	2.0	85
48	ELISA qualitative screening of chloramphenicol in muscle, eggs, honey and milk: method validation according to the Commission Decision 2002/657/EC criteria. Analytica Chimica Acta, 2005, 535, 43-48.	2.6	83
49	Performance of a componentâ€based allergenâ€microarray in the diagnosis of cow's milk and hen's egg allergy. Clinical and Experimental Allergy, 2010, 40, 1561-1570.	1.4	81
50	A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. Journal of Immunology, 2016, 196, 2492-2503.	0.4	77
51	Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Italian Journal of Pediatrics, 2018, 44, 102.	1.0	76
52	Inflammasome Activation by Cystine Crystals. Journal of the American Society of Nephrology: JASN, 2014, 25, 1163-1169.	3.0	75
53	Anakinra in children and adults with Stillâ€™s disease. Rheumatology, 2019, 58, vi9-vi22.	0.9	75
54	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	1.6	72

#	ARTICLE	IF	CITATIONS
55	Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 807-811.	6.7	71
56	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Annals of the Rheumatic Diseases, 2012, 71, i2-i45.	0.5	71
57	Deregulation of the IL-1Î² axis in chronic recurrent multifocal osteomyelitis. Pediatric Rheumatology, 2014, 12, 30.	0.9	71
58	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Research and Therapy, 2018, 20, 285.	1.6	71
59	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.5	68
60	Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2002, 46, 232-237.	6.7	67
61	Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis and Rheumatism, 2002, 46, 2721-2729.	6.7	66
62	Reaching the Threshold: A Multilayer Pathogenesis of Macrophage Activation Syndrome. Journal of Rheumatology, 2013, 40, 761-767.	1.0	64
63	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	1.0	64
64	Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade. EBioMedicine, 2015, 2, 285-293.	2.7	63
65	Catchâ€Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial. Arthritis and Rheumatology, 2015, 67, 840-848.	2.9	63
66	Targeting the interleukin-6 receptor: A new treatment for systemic juvenile idiopathic arthritis?. Arthritis and Rheumatism, 2005, 52, 687-693.	6.7	59
67	Mechanistic Associations of a Mild Phenotype of Immunodysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome. Clinical Gastroenterology and Hepatology, 2006, 4, 653-659.	2.4	59
68	IL-6 Amplifies TLR Mediated Cytokine and Chemokine Production: Implications for the Pathogenesis of Rheumatic Inflammatory Diseases. PLoS ONE, 2014, 9, e107886.	1.1	58
69	Low Serum Levels of Mannose Binding Lectin Are a Risk Factor for Neonatal Sepsis. Pediatric Research, 2007, 61, 325-328.	1.1	57
70	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	1.8	57
71	Targeting interferon-Î³ in hyperinflammation: opportunities and challenges. Nature Reviews Rheumatology, 2021, 17, 678-691.	3.5	57
72	Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations. Journal of Pediatrics, 1994, 124, 742-744.	0.9	56

#	ARTICLE	IF	CITATIONS
73	Circulating Levels of Interleukin-6, Interleukin-8, and Tumor Necrosis Factor-Î± in Children with Autoimmune Hepatitis. Journal of Pediatric Gastroenterology and Nutrition, 1995, 20, 23-27.	0.9	55
74	Self epitopes shared between human skeletal myosin andStreptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis and Rheumatism, 2002, 46, 3015-3025.	6.7	55
75	Muscle Expression of Type I and Type <scp>II</scp> Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features. Arthritis and Rheumatology, 2019, 71, 1011-1021.	2.9	55
76	Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. Journal of Pediatrics, 1994, 124, 561-565.	0.9	52
77	Symptom onset-to-balloon time and mortality in the first seven years after STEMI treated with primary percutaneous coronary intervention. Heart, 2012, 98, 1738-1742.	1.2	52
78	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet, The, 2017, 389, 909-916.	6.3	52
79	Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice. Human Molecular Genetics, 2015, 24, 6041-6053.	1.4	51
80	Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies. Best Practice and Research in Clinical Rheumatology, 2017, 31, 505-516.	1.4	49
81	Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience. Journal of Rheumatology, 2015, 42, 1523-1527.	1.0	48
82	A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNÎ³) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH. Blood, 2015, 126, LBA-3-LBA-3.	0.6	48
83	In Vivo Neutralization of Human IL-6 (hIL-6) Achieved by Immunization of hIL-6-Transgenic Mice with a hIL-6 Receptor Antagonist. Journal of Immunology, 2001, 166, 4334-4340.	0.4	47
84	Cytokines in juvenile rheumatoid arthritis. Current Opinion in Rheumatology, 1997, 9, 428-433.	2.0	44
85	Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study. Arthritis and Rheumatology, 2019, 71, 1000-1010.	2.9	44
86	Use of a mouse model to identify a blood biomarker for IFNÎ³ activity in pediatric secondary hemophagocytic lymphohistiocytosis. Translational Research, 2017, 180, 37-52.e2.	2.2	43
87	Role of mannose-binding lectin in nosocomial sepsis in critically ill neonates. Human Immunology, 2010, 71, 1084-1088.	1.2	41
88	Wolman disease associated with hemophagocytic lymphohistiocytosis: attempts for an explanation. European Journal of Pediatrics, 2014, 173, 1391-1394.	1.3	41
89	Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis.. Archives of Disease in Childhood, 1993, 69, 232-235.	1.0	40
90	Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy. Neurology, 2012, 78, 1309-1314.	1.5	40

#	ARTICLE	IF	CITATIONS
91	Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. Italian Journal of Pediatrics, 2018, 44, 103.	1.0	40
92	Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Annals of the Rheumatic Diseases, 2020, 79, 1362-1369.	0.5	39
93	Effect of IL-6 on IGF Binding Protein-3: A Study in IL-6 Transgenic Mice and in Patients with Systemic Juvenile Idiopathic Arthritis. , 0, .		39
94	The mature/pro nerve growth factor ratio is decreased in the brain of diabetic rats: Analysis by ELISA methods. Brain Research, 2015, 1624, 455-468.	1.1	38
95	Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA2 Deficiency. Journal of Rheumatology, 2019, 46, 523-526.	1.0	38
96	Association of Serum Interleukin-8 Levels with the Degree of Fibrosis in Infants with Chronic Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 540-544.	0.9	36
97	Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. American Journal of Hematology, 1994, 46, 189-193.	2.0	35
98	Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. Rheumatology, 1997, 36, 581-588.	0.9	35
99	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatric Rheumatology, 2016, 14, 68.	0.9	35
100	Role of Interleukin-6 in Growth Failure: An Animal Model. Hormone Research in Paediatrics, 2002, 58, 24-27.	0.8	34
101	Anakinra in a Cohort of Children with Chronic Nonbacterial Osteomyelitis. Journal of Rheumatology, 2017, 44, 1231-1238.	1.0	34
102	A Polymorphism in the Macrophage Migration Inhibitory Factor Promoter Is Associated With Bronchopulmonary Dysplasia. Pediatric Research, 2011, 69, 142-147.	1.1	33
103	Increased Circulating Levels of Interleukin-6 Affect the Redox Balance in Skeletal Muscle. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-13.	1.9	33
104	Tumor Necrosis Factor in Plasma and Peritoneal Fluid of Women with and without Endometriosis. Gynecologic and Obstetric Investigation, 1993, 36, 39-41.	0.7	32
105	Induction of transforming growth factor-beta 1 (TGF-beta 1), receptor expression and TGF-beta 1 protein production in retinoic acid-treated HL-60 cells: possible TGF-beta 1-mediated autocrine inhibition. Blood, 1991, 77, 1248-1255.	0.6	32
106	Targeting interleukin-6 in pediatric rheumatic diseases. Current Opinion in Rheumatology, 2009, 21, 533-537.	2.0	31
107	Safety and Efficacy of Etanercept in a Cohort of Patients with Juvenile Idiopathic Arthritis Under 4 Years of Age. Journal of Rheumatology, 2012, 39, 1287-1290.	1.0	31
108	Inflammatory events during food proteinâ€induced enterocolitis syndrome reactions. Pediatric Allergy and Immunology, 2017, 28, 464-470.	1.1	31

#	ARTICLE	IF	CITATIONS
109	NLRP2 Regulates Proinflammatory and Antiapoptotic Responses in Proximal Tubular Epithelial Cells. Frontiers in Cell and Developmental Biology, 2019, 7, 252.	1.8	31
110	Expansion of CD4dimCD8+ T cells characterizes macrophage activation syndrome and other secondary HLH. Blood, 2022, 140, 262-273.	0.6	30
111	Stimulating effect of growth hormone on cytokine release in children. European Journal of Endocrinology, 2003, 149, 397-401.	1.9	29
112	Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2020, 79, 960-968.	0.5	29
113	Dysregulation in Bâ€cell responses and T follicular helper cell function in ADA2 deficiency patients. European Journal of Immunology, 2021, 51, 206-219.	1.6	29
114	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology, 2021, 60, 3799-3808.	0.9	29
115	Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors. Arthritis and Rheumatology, 2018, 70, 606-615.	2.9	28
116	Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. Journal of Rheumatology, 2004, 31, 795-800.	1.0	28
117	Serum cytokine levels in GH-deficient children during substitutive GH therapy. European Journal of Endocrinology, 2005, 152, 207-210.	1.9	27
118	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.5	27
119	Early Treatment and IL1RN Singleâ€Nucleotide Polymorphisms Affect Response to Anakinra in SystemicÂJuvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2021, 73, 1053-1061.	2.9	27
120	Association of the macrophage migration inhibitory factor â^'173*C allele with childhood nephrotic syndrome. Pediatric Nephrology, 2008, 23, 743-748.	0.9	25
121	Relapsing polychondritis: new therapeutic strategies with biological agents. Rheumatology International, 2010, 30, 691-693.	1.5	25
122	Association Between Mannoseâ€binding Lectin Gene Polymorphisms and Necrotizing Enterocolitis in Preterm Infants. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, 160-165.	0.9	25
123	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. Frontiers in Pharmacology, 2019, 10, 918.	1.6	25
124	IFNAR2 Deficiency Causing Dysregulation of NK Cell Functions and Presenting With Hemophagocytic Lymphohistiocytosis. Frontiers in Genetics, 2020, 11, 937.	1.1	25
125	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Research and Therapy, 2020, 22, 71.	1.6	25
126	Interleukin-18 in pediatric rheumatic diseases. Current Opinion in Rheumatology, 2019, 31, 421-427.	2.0	23

#	ARTICLE	IF	CITATIONS
127	The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia. Leukemia, 2005, 19, 2346-2347.	3.3	22
128	The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis. PLoS ONE, 2019, 14, e0226043.	1.1	22
129	Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA). Pediatric Rheumatology, 2014, 12, .	0.9	21
130	An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA). Pediatric Rheumatology, 2018, 16, 27.	0.9	21
131	Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. European Journal of Paediatric Neurology, 2012, 16, 301-303.	0.7	20
132	The Impact of Chronic Inflammation on the Growing Skeleton: Lessons from Interleukin-6 Transgenic Mice. Hormone Research, 2009, 72, 26-29.	1.8	19
133	Monocytes and macrophages as biomarkers for the diagnosis of megalencephalic leukoencephalopathy with subcortical cysts. Molecular and Cellular Neurosciences, 2013, 56, 307-321.	1.0	19
134	Systemic Juvenile Idiopathic Arthritis. , 2016, , 205-216.e6.		19
135	ProNGF-p75NTR axis plays a proinflammatory role in inflamed joints: a novel pathogenic mechanism in chronic arthritis. RMD Open, 2017, 3, e000441.	1.8	19
136	Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factorâ€“negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication. Journal of Rheumatology, 2018, 45, 956-961.	1.0	19
137	Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology, 2021, 60, 4568-4580.	0.9	18
138	Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. Rheumatology, 1999, 38, 773-773.	0.9	17
139	Mutations at the C-terminus of CDC42 cause distinct hematopoietic and autoinflammatory disorders. Journal of Allergy and Clinical Immunology, 2022, 150, 223-228.	1.5	17
140	Increased Risk of Invasive Meningococcal Disease, Pregnancy, and Confounding. Pediatrics, 2005, 116, 798-799.	1.0	16
141	SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2011, , 236-248.		16
142	Efficacy and Safety of Tocilizumab for Polyarticularâ€Course Juvenile Idiopathic Arthritis in the Openâ€Label Twoâ€Year Extension of a Phase III Trial. Arthritis and Rheumatology, 2021, 73, 530-541.	2.9	16
143	Juvenile Idiopathic Arthritis. BioDrugs, 2000, 14, 93-98.	2.2	15
144	Renal involvement in hypocomplementaemic urticarial vasculitis syndrome: a report of three paediatric cases. Rheumatology, 2014, 53, 1409-1413.	0.9	15

#	Article	IF	Citations
145	Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study. Rheumatology, 2018, 57, 1752-1760.	0.9	15
146	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. Frontiers in Pharmacology, 2018, 9, 1526.	1.6	15
147	OP0204â€…EMAPALUMAB, AN INTERFERON GAMMA (IFN-Y)-BLOCKING MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). , 2019, , .		15
148	Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis. Blood, 2018, 132, LBA-6-LBA-6.	0.6	15
149	Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry. Journal of Rheumatology, 2022, 49, 398-407.	1.0	15
150	Tocilizumab for Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2013, 368, 1256-1257.	13.9	14
151	A56: Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab. Arthritis and Rheumatology, 2014, 66, S83.	2.9	14
152	Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids. Frontiers in Pediatrics, 2020, 8, 576912.	0.9	14
153	Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. Lancet Rheumatology, The, 2021, 3, e563-e573.	2.2	14
154	OP0290â€…EMAPALUMAB (ANTI-INTERFERON-GAMMA MONOCLONAL ANTIBODY) IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). Annals of the Rheumatic Diseases, 2020, 79, 180.1-180.	0.5	14
155	High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. Clinical and Experimental Immunology, 2003, 131, 355-363.	1.1	13
156	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2019, 46, 1117-1126.	1.0	13
157	Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome?. Pediatric Rheumatology, 2019, 17, 84.	0.9	13
158	Anti interferon-gamma (IFNÎ³) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis. Pediatric Rheumatology, 2015, 13, .	0.9	12
159	A patient with stimulator of interferon genesâ€“associated vasculopathy with onset in infancy without skin vasculopathy. Rheumatology, 2020, 59, 905-907.	0.9	11
160	Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma. Frontiers in Immunology, 2021, 12, 663329.	2.2	11
161	CD5-Positive B cells in type 1 (insulin-dependent) diabetic children. Diabetes Research and Clinical Practice, 1993, 19, 17-22.	1.1	10
162	The activating p.Ser466Arg change in STAT1 causes a peculiar phenotype with features of interferonopathies. Clinical Genetics, 2019, 96, 585-589.	1.0	10

#	ARTICLE	IF	CITATIONS
163	Assessment of disease activity using a whole-body MRI derived radiological activity index in chronic nonbacterial osteomyelitis. Pediatric Rheumatology, 2021, 19, 123.	0.9	10
164	LACK OF TEMPORAL ASSOCIATION OF IRIDOCYCLITIS WITH IgG REACTIVITIES TO CORE HISTONES AND NUCLEOSOME SUBPARTICLES IN PAUCIARTICULAR JUVENILE CHRONIC ARTHRITIS. Rheumatology, 1995, 34, 507-511.	0.9	9
165	Industrial Synthesis of 4-Chloro,11Î²-arylestradiol: How to Circumvent a Poor Diastereoselectivity. Organic Process Research and Development, 2004, 8, 219-228.	1.3	9
166	A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. Arthritis and Rheumatology, 2014, 66, S8-S9.	2.9	9
167	Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial. Journal of Rheumatology, 2018, 45, 1173-1179.	1.0	9
168	Different responses of PC12â€¯cells to different pro-nerve growth factor protein variants. Neurochemistry International, 2019, 129, 104498.	1.9	9
169	An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Pediatric Rheumatology, 2019, 17, 25.	0.9	9
170	Sustained Systemic Levels of IL-6 Impinge Early Muscle Growth and Induce Muscle Atrophy and Wasting in Adulthood. Cells, 2021, 10, 1816.	1.8	9
171	Visceral leishmaniasis as a cause of unexplained fever and cytopenia in systemic lupus erythematosus. Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 246-247.	0.7	8
172	FRI0328â€…Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial. Annals of the Rheumatic Diseases, 2013, 71, 425.1-425.	0.5	8
173	An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6. Osteoporosis International, 2014, 25, 681-692.	1.3	8
174	Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2019, 71, 1976-1984.	2.9	8
175	Hemoperfusion with CytoSorb to Manage Multiorgan Dysfunction in the Spectrum of Hemophagocytic Lymphohistiocytosis Syndrome in Critically Ill Children. Blood Purification, 2022, 51, 417-424.	0.9	8
176	Caspase-1 levels in biological fluids from patients with multiple sclerosis and from patients with other neurological and non-neurological diseases. European Cytokine Network, 2002, 13, 99-103.	1.1	8
177	Increased expression of alpha(1,3)-fucosyltransferase-VII and P-selectin binding of synovial fluid T cells in juvenile idiopathic arthritis. Journal of Rheumatology, 2003, 30, 1611-5.	1.0	8
178	Decreased fibrinolytic activity in juvenile chronic arthritis.. Annals of the Rheumatic Diseases, 1990, 49, 973-975.	0.5	7
179	High levels of interferon-gamma (IFNÎ³) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNÎ³ production in MAS. Pediatric Rheumatology, 2015, 13, .	0.9	7
180	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. Arthritis Research and Therapy, 2020, 22, 211.	1.6	7

#	ARTICLE	IF	CITATIONS
181	Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts. Frontiers in Immunology, 2021, 12, 656407.	2.2	7
182	Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model. Pediatric Rheumatology, 2014, 12, .	0.9	6
183	Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis: Table 1.. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 76-79.	0.6	6
184	Pro Nerve Growth Factor and Its Receptor p75NTR Activate Inflammatory Responses in Synovial Fibroblasts: A Novel Targetable Mechanism in Arthritis. Frontiers in Immunology, 2022, 13, 818630.	2.2	6
185	The pediatric glucocorticoid toxicity index. Seminars in Arthritis and Rheumatism, 2022, 56, 152068.	1.6	6
186	The macrophage migration inhibitory factor â^'173G/C polymorphism is not significantly associated with necrotizing enterocolitis in preterm infants. Journal of Pediatric Surgery, 2013, 48, 1499-1502.	0.8	5
187	Inhibition of natural killer (nk) cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Pediatric Rheumatology, 2014, 12, P56.	0.9	5
188	A45: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, S67-S68.	2.9	5
189	A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, S23-S24.	2.9	5
190	Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Pediatric Rheumatology, 2014, 12, .	0.9	5
191	Fused Omics Data Models Reveal Gut Microbiome Signatures Specific of Inactive Stage of Juvenile Idiopathic Arthritis in Pediatric Patients. Microorganisms, 2020, 8, 1540.	1.6	5
192	Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort. Rheumatology, 2022, 61, 1621-1629.	0.9	5
193	Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus. Pediatric Rheumatology, 2021, 19, 144.	0.9	5
194	Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNÎ³) Monoclonal Antibody. Blood, 2021, 138, 2058-2058.	0.6	5
195	It is about time: the first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis. Rheumatology, 2022, 61, 2724-2725.	0.9	5
196	Anti-DNA Antibodies in the Primary Antiphospholipid Syndrome. Rheumatology, 1993, 32, 1028-1028.	0.9	4
197	Mechanisms inducing low bone density in Duchenne Muscular Dystrophy. Bone, 2009, 44, S237-S238.	1.4	4
198	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. Arthritis and Rheumatology, 2014, 66, S17-S18.	2.9	4

#	ARTICLE	IF	CITATIONS
199	A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study. Arthritis and Rheumatology, 2014, 66, S80-S81.	2.9	4
200	A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. Arthritis and Rheumatology, 2014, 66, S5-S6.	2.9	4
201	The phenotypic variability of PAPA syndrome: evidence from the Eurofever Registry. Pediatric Rheumatology, 2015, 13, .	0.9	4
202	FRI0488â€…A Phase Iii Pivotal Umbrella Trial of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). Annals of the Rheumatic Diseases, 2016, 75, 615.2-616.	0.5	4
203	Functional Ability and Healthâ€Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2020, 73, 1264-1274.	1.5	4
204	Visceral leishmaniasis as a cause of unexplained fever and cytopenia in systemic lupus erythematosus. Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 246-7.	0.7	4
205	Effects of Retinoic Acid on TGF? Receptor Expression in HL-60 Cells. Annals of the New York Academy of Sciences, 1990, 593, 310-312.	1.8	3
206	Secondary thrombocytosis.. Archives of Disease in Childhood, 1993, 69, 170-171.	1.0	3
207	Repositioning agricultural development in Africa through appropriate technology transfer. African Journal of Science, Technology, Innovation and Development, 2014, 6, 45-50.	0.8	3
208	Chronic recurrent multifocal osteomyelitis (CRMO): typical patterns of bone involvement on MRI with particular emphasis on Whole Body MRI (WBMRI). Pediatric Rheumatology, 2015, 13, .	0.9	3
209	Whole-Body MRI versus bone scintigraphy: which is the best diagnostic tool in patients with chronic recurrent multifocal osteomyelitis (CRMO)?. Pediatric Rheumatology, 2015, 13, .	0.9	3
210	THU0509â€…Improvement of disease activity in patients with colchicine-resistant FMF, HIDS/MKD and traps assessed by autoinflammatory disease activity index (AIDAI): results from the cluster trial. , 2017, , .		3
211	Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study . Biologics: Targets and Therapy, 2020, Volume 14, 13-21.	3.0	3
212	Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNÎ³) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases. Blood, 2021, 138, 4195-4195.	0.6	3
213	Morphology of the Gastric Mucosa, Gastric Secretion and Serum Gastrin Concentration following a Test Meal. Digestion, 1978, 17, 18-28.	1.2	2
214	Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis.. Annals of the Rheumatic Diseases, 1989, 48, 582-585.	0.5	2
215	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2â€Year Results From the TENDER Trial. Arthritis and Rheumatology, 2014, 66, S96.	2.9	2
216	Neutralization of Interferon-gamma is efficacious in a mouse model of HLH secondary to chronic inflammation. Pediatric Rheumatology, 2015, 13, .	0.9	2

#	ARTICLE	IF	CITATIONS
217	S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH. Pediatric Rheumatology, 2015, 13, .	0.9	2
218	Single center experience in Next Generation Sequencing for genetic diagnosis of Autoinflammatory Disorders (AIDs). Pediatric Rheumatology, 2015, 13, .	0.9	2
219	FRI0489â€…Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 616.1-616.	0.5	2
220	THU0503â€…Identification of optimal subcutaneous (SC) doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis (PCJIA). , 2017, , .		2
221	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 251-258.	1.5	2
222	FRI0549â€…SARILUMAB, A HUMAN MONOCLONAL ANTIBODY TO THE INTERLEUKIN-6 (IL-6) RECEPTOR, IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): A 12-WEEK MULTINATIONAL OPEN-LABEL DOSE-FINDING STUDY. , 2019, , .		2
223	SAT0490â€…IL-1 BLOCKADE IN PEDIATRIC RECURRENT PERICARDITIS: A MULTICENTRIC RETROSPECTIVE STUDY ON THE ITALIAN COHORT. , 2019, , .		2
224	IgM on the surface of T cells: a novel biomarker of pediatric-onset systemic lupus erythematosus. Pediatric Nephrology, 2021, 36, 909-916.	0.9	2
225	Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial. Rheumatology, 2022, 61, 2088-2094.	0.9	2
226	THU0570â€…Long-term efficacy and safety of canakinumab in patients with colchicine-resistant fmf (CRFMF), traps and hids/mkd: results from the pivotal phase 3 cluster trial. , 2018, , .		2
227	Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey. Clinical and Experimental Rheumatology, 2019, 37, 1084-1091.	0.4	2
228	Acute rheumatic fever prophylaxis in high-income countries: clinical observations from an Italian multicentre, retrospective study. Clinical and Experimental Rheumatology, 2020, 38, 1016-1020.	0.4	2
229	Reciprocal interactions between the GH/IGF-I system and cytokines. NeuroImmune Biology, 2002, , 27-35.	0.2	1
230	MECHANISMS INDUCING LOW BONE DENSITY IN DUCHENNE MUSCULAR DYSTROPHY. Bone, 2010, 46, S79-S80.	1.4	1
231	OP0062â€…The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Serious Adverse Events. The 5882 Pharmachild Cohort. Annals of the Rheumatic Diseases, 2015, 74, 91-91.	0.5	1
232	Interferon gamma (IFNg) drives disease in the TLR9-mediated cytokine storm syndrome in mice. Pediatric Rheumatology, 2015, 13, .	0.9	1
233	Interleukin-1 receptor antagonist treatment revealed active hepatitis B infection in a boy with PAPA syndrome. Pediatric Rheumatology, 2015, 13, .	0.9	1
234	THU0569â€…Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). Annals of the Rheumatic Diseases, 2016, 75, 397.3-398.	0.5	1

#	ARTICLE	IF	CITATIONS
235	Macrophage Activation Syndrome in Rheumatic Diseases (MAS-HLH). , 2018, , 233-246.		1
236	FRI0554â€…DNASE1L3 VARIANT IN HYPOCOMPLEMENTEMIC URTICARIAL VASCULITIS SYNDROME IDENTIFIES A DIFFERENT CLINICAL PHENOTYPE. , 2019, , .		1
237	OP0057â€…EARLY TREATMENT WITH ANAKINRA IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		1
238	FRI0540â€…A NOVEL AUTOINFLAMMATORY DISEASE CHARACTERIZED BY NEONATAL-ONSET CYTOPENIA WITH AUTOINFLAMMATION, RASH, AND HEMOPHAGOCYTOSIS (NOCARH) DUE TO ABERRANT CDC42 FUNCTION. , 2019, , .		1
239	AB1059â€…A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ANAKINRA IN PATIENTS WITH STILLÂ´S DISEASE. Annals of the Rheumatic Diseases, 2020, 79, 1819.2-1820.	0.5	1
240	Synergy between Transforming Growth Factor-? and Tumor Necrosis Factor-? in the Induction of Monocytic Differentiation of Human Leukemic Cell Lines. Annals of the New York Academy of Sciences, 1990, 593, 334-337.	1.8	0
241	203 Low Mannose Binding Lectin (MBL) Serum Levels And Hospital Acquired Infections (HAI) in Neonates in a Neonatal Intensive Care Unit (NICU). Pediatric Research, 2004, 56, 498-498.	1.1	0
242	D.P.3.10 Partial caveolin 3 deficiency in acquired rippling muscle disease. Neuromuscular Disorders, 2008, 18, 767-768.	0.3	0
243	Inhibition of c-Src reduces IL-6 expression in vivo and in vitro. Bone, 2009, 44, S249.	1.4	0
244	Mechanisms underlying low bone density in muscular dystrophy. Bone, 2009, 45, S60-S61.	1.4	0
245	Eosinophilic Esophagitis and IgE Mediated Allergy in Children: Detection of Specific IgE by a Microarray-Based assay (MBa). Journal of Allergy and Clinical Immunology, 2011, 127, AB108-AB108.	1.5	0
246	Macrophage Migration Inhibitory Factor -173 G/C Polymorphism is Not Associated with An Increased Risk of Necrotizing Enterocolitis in Preterm Neonates in NICU. Pediatric Research, 2011, 70, 714-714.	1.1	0
247	Acute rheumatic fever with chorea. Archives of Disease in Childhood, 2013, 98, 203-203.	1.0	0
248	OP0175â€…The eurofever registry for autoinflammatory disease: Update on enrollment after 2 years. Annals of the Rheumatic Diseases, 2013, 71, 114.1-114.	0.5	0
249	A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12, .	0.9	0
250	A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight. Arthritis and Rheumatology, 2014, 66, S222.	2.9	0
251	Clinical presentation and cytokine production abnormalities in a cohort of patients carrying NLRP12 gene variants. Pediatric Rheumatology, 2014, 12, .	0.9	0
252	Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial. Rheumatology, 2014, 53, iii1-iii1.	0.9	0

#	ARTICLE	IF	CITATIONS
253	Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: 2-year data from the CHERISH study. Rheumatology, 2014, 53, iii1-iii2.	0.9	0
254	Kikuchi-Fujimoto disease in patient with systemic phacomatosis pigmentovascularis. Blood Coagulation and Fibrinolysis, 2014, 25, 783-785.	0.5	0
255	THU0508â€...Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: 5-Year Data from Tender, A Phase 3 Clinical Trial. Annals of the Rheumatic Diseases, 2015, 74, 384.1-384.	0.5	0
256	Inflammatory Cytokine response in a cohort of patients carrying novel NLRP12 variants. Pediatric Rheumatology, 2015, 13, .	0.9	0
257	SAT0483â€...Tapering and Withdrawal of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results from an Alternative Dosing Regimen in the Tender Study. Annals of the Rheumatic Diseases, 2015, 74, 835.1-835.	0.5	0
258	FRI0323â€...Cronic Non-Bacterial Osteomyelitis (CNO) in a Cohort of Pediatric Patients: Clinical, Biological and Radiological Response to Treatment with Anakinra. Annals of the Rheumatic Diseases, 2015, 74, 541.2-541.	0.5	0
259	OP0134â€...Increased Muscle Interferon-Î³ Expression Levels in Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2015, 74, 119.1-119.	0.5	0
260	OP0008â€...Single Center Experience in Next Generation Sequencing for Genetic Diagnosis of Autoinflammatory Disorders (AIDS). Annals of the Rheumatic Diseases, 2015, 74, 67.1-67.	0.5	0
261	Cronic non-bacterial osteomyelitis (CNO) in a cohort of pediatric patients: clinical, biological and radiological response to treatment with Anakinra. Pediatric Rheumatology, 2015, 13, .	0.9	0
262	PP11. Assessment of radiographic progression in patients with systemic juvenile idiopathic arthritis treated with tocilizumab: 2-year data from tender. Rheumatology, 2015, 54, ii9-ii9.	0.9	0
263	SAT0325â€...Chronic Recurrent Multifocal Osteomyelitis (CRMO): Typical Patterns of Bone Involvement on MRI with Particular Emphasis on Whole Body MRI (WBMRI). Annals of the Rheumatic Diseases, 2015, 74, 776.2-776.	0.5	0
264	OP0217â€...Adjudication of Infections in The Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated with Biologic Agents and/or Methotrexate. Annals of the Rheumatic Diseases, 2016, 75, 139.1-139.	0.5	0
265	OP0063â€...Canakinumab treatment in patients with colchicine-resistant FMF (CRFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40. , 2017, , .		0
266	Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases. , 2019, , 751-774.		0
267	OP0059â€...PERIARTICULAR GLUCOCORTICOID INJECTIONS: DELINEATING THEIR USE IN JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
268	AB0932â€...PREDICTORS OF FLARE FOLLOWING ETANERCEPT WITHDRAWAL IN PATIENTS WITH RHEUMATOID FACTOR NEGATIVE JUVENILE IDIOPATHIC ARTHRITIS DURING 48 MONTHS OF FOLLOW-UP. , 2019, , .		0
269	AB0940â€...OBESITY AND NUMBER OF ACTIVE JOINTS AT TUMOR NECROSIS FACTOR-INHIBITOR START ARE ASSOCIATED WITH SHORTER REMISSION DURATION AFTER WITHDRAWAL IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: PRELIMINARY RESULTS FROM A MONOCENTRIC COHORT. , 2019, , .		0
270	AB0185â€...INTERFERON-Î“ AMPLIFIES IMMUNE RESPONSE MEDIATED BY TYPE I INTERFERONS IN PAEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS AND CORRELATES WITH DISEASE ACTIVITY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
271	FRI0572â€…DISABILITY AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL. , 2019, , .		0
272	OP0254â€…CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER). , 2019, , .		0
273	AB0989â€…PATIENTSâ€™ AND CAREGIVERSâ€™ ASSESSMENT OF A DEDICATED OUTPATIENT SERVICE FOR INTRAARTICULAR GLUCOCORTICOID INJECTIONS IN JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
274	THU0507â€…TYPE I INTERFERON SCORE AND INTERFERON INDUCED MEDIATORS CXCL10 AND NEOPTERIN ARE CORRELATED WITH DISEASE ACTIVITY IN JUVENILE DERMATOMYOSITIS. , 2019, , .		0
275	THU0517â€…THE LONGITUDINAL EUROFEVER PROJECT: AN UPDATE ON ENROLLMENT. , 2019, , .		0
276	OP0258â€…LESSON FROM EUROFEVER REGISTRY AFTER THE FIRST TEN YEARS OF ENROLLMENT. , 2019, , .		0
277	OP0255â€…MICROBIOTA TRANSPLANT TO CONTROL INFLAMMATION IN A NLRC4-RELATED DISEASE PATIENT WITH RECURRENT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH). , 2019, , .		0
278	FRI0539â€…WNT6 MUTATION CAUSES AN EARLY ONSET GRANULOMATOSUS INTESTINAL DISEASE WITH RECURRENT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH). , 2019, , .		0
279	THU0527â€…RISK SCORE OF MACROPHAGE ACTIVATION SYNDROME IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
280	THU0516â€…LONG-TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTRATION IN SYSTEMIC AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
281	FRI0542â€…CLINICAL PRESENTATION, GENETIC ANALYSIS AND IFN-SCORE IN PATIENTS WITH UNDEFINED INTERFERONOPATHIES. , 2019, , .		0
282	SAT0497â€…CLINICAL PICTURE OF 7 PAPA PATIENTS FOLLOWED IN A SINGLE PEDIATRIC RHEUMATOLOGIC CENTER. , 2019, , .		0
283	THU0530â€…IDIOPATHIC RECURRENT PERICARDITIS: CLINICAL FINDINGS AND TREATMENT APPROACH. , 2019, , .		0
284	THU0550â€…MYCOPHENOLATE MOFETIL (MMF) IN DEFINED AND UNDEFINED INTERFERONOPATHIES. , 2019, , .		0
285	AB1069â€…HYPERZINCAEMIA AND HYPERCALPROTECTINEMIA SYNDROME: MORE THAN JUST AUTOINFLAMMATION?. , 2019, , .		0
286	THU0513â€…WHOLE BLOOD CELLS FROM PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) IN CLINICAL INACTIVE DISEASE DISPLAY A DYSREGULATED RESPONSE TO TLR-4 STIMULATION. , 2019, , .		0
287	AB1062â€…INTER-LABORATORY COMPARISON OF TYPE I INTERFERON SIGNATURE ANALYSES: PAVING THE WAY TO SHARE RECOMMENDATIONS.. , 2019, , .		0
288	Response to: â€˜Correspondence on â€˜Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trialâ€™â€™ by Satiset al. Annals of the Rheumatic Diseases, 2022, 81, e257-e257.	0.5	0

#	ARTICLE	IF	CITATIONS
289	A rare cause of multiple airways narrowing in a 15-year-old girl. Thorax, 2021, 76, 205-207.	2.7	0
290	Reumatologia. Medico E Bambino, 2021, 40, 1-3.	0.1	0
291	Impact of chronic inflammation on bone during childhood. Future Rheumatology, 2006, 1, 455-464.	0.2	0
292	ANTIBODIES TO HISTONES IN AUTOIMMUNE HEPATITIS OF CHILDHOOD. Journal of Pediatric Gastroenterology and Nutrition, 1997, 24, 486.	0.9	0
293	SAT0386â€…Adjudication of infections from the pharmacovigilance in juvenile idiopathic arthritis patients (PHARMACHILD) treated with biologic agents and/or methotrexate: update on results with a focus on opportunistic infections. , 2018, , .		0
294	OP0103â€…Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis. , 2018, , .		0
295	Anti-interferon-Î³ Therapy for Cytokine Storm Syndromes. , 2019, , 569-580.		0
296	AB1404-HPRâ€…JIA TEAMWORK FOR IMPROVING PATIENTSâ€™ ACCEPTANCE OF INTRAARTICULAR GLUCOCORTICOID INJECTIONS IN LOCAL ANESTHESIA IN OUTPATIENT DEDICATED SERVICE. , 2019, , .		0
297	OP0272â€…LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM THE RANDOMISED PHASE 3 CLUSTER TRIAL. Annals of the Rheumatic Diseases, 2020, 79, 169.2-170.	0.5	0